Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brooks Taylor R, Zabor Emily C, Bedelu Yohanna B, Yang Xi, Karimi Yasmin H, Nedved Adrienne N, Wang Yucai, Dave Nikita, Landsburg Daniel J, Baron Kelsey, Hu Boyu, Trotier Daniel C, Pophali Priyanka A, Miller Jordan, Grover Natalie, Reinert Catherine, Major Ajay, Schwarz Tenley, Patel Krish, Salafian Kiarash, Ayers Emily, Sundaram Suchitra, Brody Joshua D, McKenna Marshall, Ryu Tiger Yun Kyoung, Sears-Smith Megan, Ghosh Nilanjan, Peterson Chelsea, Khan Cyrus, Bliven Sean P, Narkhede Mayur, Gibson Alyssa, Kline Justin, Munoz Javier, Garza-Morales Rodolfo, Ho Carrie I, Smith Stephen D, Niu Alex, Hernandez-Ilizaliturri Francisco, Chinyengetere Fadzai, Dave Sandeep, Abdel-Razeq Nayef, Moustafa Muhamad Alhaj, Caimi Paolo F, Hill Brian T
Аннотация
Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.